Skip to main content
Top
Published in: Clinical Rheumatology 11/2011

01-11-2011 | Original Article

Estimation of BVAS in patients with microscopic polyangiitis in Japan

Authors: Mitsuyo Itabashi, Takashi Takei, Taku Morito, Yasuko Yabuki, Hitoe Suzuki, Minoru Ando, Mayuko Akamatsu, Mayuko Yamazaki, Michihiro Mitobe, Yoshihiko Watanabe, Takahiro Mochizuki, Kosaku Nitta

Published in: Clinical Rheumatology | Issue 11/2011

Login to get access

Abstract

The validity of the Birmingham Vasculitis Activity Score (BVAS) as an index of disease activity and a predictor of the prognosis and outcome in patients with MPA has not yet been established in Japan. We conducted a retrospective study of the data of 73 patients with MPA who were followed up for at least 2 years. We divided the patients into two groups according to the BVAS, namely, the high-BVAS group (≥16) and the low-BVAS group (<16), and compared the clinical characteristics. In addition, the distribution of the BVAS items in the patients and the items contributing to the total score in MPA patients were analyzed. Remission was achieved in 85% of patients at 1 month. There were no significant differences in the serum CRP, creatinine (Cre), or MPO-ANCA between the high- and low-BVAS group; however, the survival time was significantly shorter (p = 0.048) and the mortality rate significantly higher in the high-BVAS group (p = 0.04). The items of the BVAS contributing to the total score were motor neuropathy, sensory neuropathy, pulmonary infiltrate, hematuria, proteinuria, Cre ≥5.6 mg/dL, hypertension, scleritis, rise in Cre by ≥30%, and myalgia. BVAS was found to be a useful tool for determining the disease activity and outcome in patients with MPA in Japan. The initial BVAS was also predictive of the mortality and survival time and can also be used as a prognostic tool; therefore, use of the tool may facilitate the selection of appropriate treatment.
Literature
2.
go back to reference Jennette JC, Falk RJ (1998) Pathogenesis of the vascular and glomerular damage in ANCA-positive vasculitis. Nephrol Dial Transplant 13(Suppl 1):16–20PubMedCrossRef Jennette JC, Falk RJ (1998) Pathogenesis of the vascular and glomerular damage in ANCA-positive vasculitis. Nephrol Dial Transplant 13(Suppl 1):16–20PubMedCrossRef
3.
go back to reference Watts RA, Scott DGI (2003) Overview of the inflammatory vasculitides. In: Hochberg MC, Silman A, Smolen JS, Weinblatt ME, Weissman MH (eds) Rheumatology, 3rd edn. Mosby, New York, pp 1583–1591 Watts RA, Scott DGI (2003) Overview of the inflammatory vasculitides. In: Hochberg MC, Silman A, Smolen JS, Weinblatt ME, Weissman MH (eds) Rheumatology, 3rd edn. Mosby, New York, pp 1583–1591
4.
go back to reference Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 37:187–192PubMedCrossRef Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 37:187–192PubMedCrossRef
5.
go back to reference Basu N, Watts R, Bajema I, Baslund B, Bley T, Boers M, Brogan P, Calabrese L, Cid MC, Cohen-Tervaert JW, Flores-Suarez LF, Fujimoto S, de Groot K, Guillevin L, Hatemi G, Hauser T, Jayne D, Jennette C, Kallenberg CG, Kobayashi S, Little MA, Mahr A, McLaren J, Merkel PA, Ozen S, Puechal X, Rasmussen N, Salama A, Salvarani C, Savage C, Scott DG, Segelmark M, Specks U, Sunderköetter C, Suzuki K, Tesar V, Wiik A, Yazici H, Luqmani R (2010) EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 69:1744–1750PubMedCrossRef Basu N, Watts R, Bajema I, Baslund B, Bley T, Boers M, Brogan P, Calabrese L, Cid MC, Cohen-Tervaert JW, Flores-Suarez LF, Fujimoto S, de Groot K, Guillevin L, Hatemi G, Hauser T, Jayne D, Jennette C, Kallenberg CG, Kobayashi S, Little MA, Mahr A, McLaren J, Merkel PA, Ozen S, Puechal X, Rasmussen N, Salama A, Salvarani C, Savage C, Scott DG, Segelmark M, Specks U, Sunderköetter C, Suzuki K, Tesar V, Wiik A, Yazici H, Luqmani R (2010) EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 69:1744–1750PubMedCrossRef
6.
go back to reference Guillevin L, Durand-Gasselin B, Cevallos R et al (1999) Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42:421–430PubMedCrossRef Guillevin L, Durand-Gasselin B, Cevallos R et al (1999) Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42:421–430PubMedCrossRef
7.
go back to reference Fujimoto S, Uezono S, Hisanaga S, Fukudome K, Kobayashi S, Suzuki K et al (2006) Incidence of ANCA-associated primary renal vasculitis in Miyazaki prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol 1:1016–1022PubMedCrossRef Fujimoto S, Uezono S, Hisanaga S, Fukudome K, Kobayashi S, Suzuki K et al (2006) Incidence of ANCA-associated primary renal vasculitis in Miyazaki prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol 1:1016–1022PubMedCrossRef
8.
go back to reference Luqmani RA, Bacon PA, Moots RJ et al (1994) Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87:671–678PubMed Luqmani RA, Bacon PA, Moots RJ et al (1994) Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87:671–678PubMed
9.
go back to reference Lane SE, Watts RA, Shepstone L, Scott DG (2005) Primary systemic vasculitis: clinical features and mortality. QJM 98:97–111PubMedCrossRef Lane SE, Watts RA, Shepstone L, Scott DG (2005) Primary systemic vasculitis: clinical features and mortality. QJM 98:97–111PubMedCrossRef
10.
go back to reference Flossmann O, Bacon P, de Groot K et al (2007) Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 66:283–292PubMed Flossmann O, Bacon P, de Groot K et al (2007) Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 66:283–292PubMed
11.
go back to reference Mukhtyar C, Lee R, Brown D et al (2009) Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis 68:1827–1832PubMedCrossRef Mukhtyar C, Lee R, Brown D et al (2009) Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis 68:1827–1832PubMedCrossRef
12.
go back to reference Imai E, Matsuo S, Makino H et al (2008) Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res 31:1101–1107PubMedCrossRef Imai E, Matsuo S, Makino H et al (2008) Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res 31:1101–1107PubMedCrossRef
13.
go back to reference Watts RA, Lane SE, Bentham G, Scott DG (2000) Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 43:414–419PubMedCrossRef Watts RA, Lane SE, Bentham G, Scott DG (2000) Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 43:414–419PubMedCrossRef
14.
go back to reference Watts RA, Scott DG, Jayne DRW, Ito-Ihara T, Muso E, Fujimoto S et al (2008) Renal vasculitis in Japan and UK—are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant 23:3743–3745CrossRef Watts RA, Scott DG, Jayne DRW, Ito-Ihara T, Muso E, Fujimoto S et al (2008) Renal vasculitis in Japan and UK—are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant 23:3743–3745CrossRef
15.
go back to reference Lane SE, Scott DG, Heaton A, Watts RA (2000) Primary renal vasculitis in Norfolk—increasing incidence or increasing recognition? Nephrol Dial Transplant 15:23–27PubMedCrossRef Lane SE, Scott DG, Heaton A, Watts RA (2000) Primary renal vasculitis in Norfolk—increasing incidence or increasing recognition? Nephrol Dial Transplant 15:23–27PubMedCrossRef
16.
go back to reference Green H, Paul M, Vidal L, Leibovici L (2007) Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82:1052–1059PubMedCrossRef Green H, Paul M, Vidal L, Leibovici L (2007) Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82:1052–1059PubMedCrossRef
17.
go back to reference Koyama A, Yamagata K, Makini H, Arimura Y, Wada T, Nitta K, Nihei H, Muso E, Taguma Y, Shigematsu H, Sakai H, Tomino Y, Matsuo S, Japan RPGN Registry Group (2009) A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol 13:633–650PubMedCrossRef Koyama A, Yamagata K, Makini H, Arimura Y, Wada T, Nitta K, Nihei H, Muso E, Taguma Y, Shigematsu H, Sakai H, Tomino Y, Matsuo S, Japan RPGN Registry Group (2009) A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol 13:633–650PubMedCrossRef
18.
go back to reference Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, Jarrousse B, French Vasculitis Study Group (2001) Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg–Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44:666–675PubMedCrossRef Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, Jarrousse B, French Vasculitis Study Group (2001) Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg–Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44:666–675PubMedCrossRef
19.
go back to reference Guillevin L, Durand-Gasselin B, Cevallos R, Gaylaud M et al (1999) Microscopic polyangiitis. Arthritis Rheum 42:421–430PubMedCrossRef Guillevin L, Durand-Gasselin B, Cevallos R, Gaylaud M et al (1999) Microscopic polyangiitis. Arthritis Rheum 42:421–430PubMedCrossRef
Metadata
Title
Estimation of BVAS in patients with microscopic polyangiitis in Japan
Authors
Mitsuyo Itabashi
Takashi Takei
Taku Morito
Yasuko Yabuki
Hitoe Suzuki
Minoru Ando
Mayuko Akamatsu
Mayuko Yamazaki
Michihiro Mitobe
Yoshihiko Watanabe
Takahiro Mochizuki
Kosaku Nitta
Publication date
01-11-2011
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 11/2011
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1838-7

Other articles of this Issue 11/2011

Clinical Rheumatology 11/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine